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ABSTRACT
Short precorneal residence time and poor transocular membrane
permeability are the major challenges associated with topical
ocular drug delivery. In the present research, the efficiency of
the electrolyte-triggered sol-to-gel–forming system of natamy-
cin (NT) transfersomes was investigated for enhanced and
prolonged ophthalmic delivery. Transfersomes were optimized
by varying the molar ratios of phospholipid, sorbitan monostea-
rate (Span) and tocopheryl polyethylene glycol succinate (TPGS).
NT transfersome formulations (FNs) prepared with a 1:1 molar
ratio of phospholipid-to-Span and low levels of TPGS showed
optimal morphometric properties, and were thus selected to
fabricate the in situ gelling system. Gellan gum–based (0.3% w/v)
FN-loaded formulations (FNGs) immediately formed an in situ gel
in the simulated tear fluid, with considerable viscoelastic charac-
teristics. In vitro cytotoxicity in corneal epithelial cells and corneal
histology studies demonstrated the ocular safety and cytocom-
patibility of these optimized formulations. Transcorneal perme-
ability of NT from these formulations was significantly higher than
in the control suspension. Moreover, the ocular disposition studies
of NT, from the FNs and FNGs, in New Zealandmale albino rabbits
demonstrated the superiority of the electrolyte-sensitive FNGs in
terms of NT delivery to the ocular tissues.
Introduction
Drug delivery to the eye, through the topical route, has been
an intricate conundrum owing to its complex structure with
various static and dynamic barriers (Urtti, 2006; Patel et al.,
2013; Rowe-Rendleman et al., 2014). Rapid clearance from
the precorneal space and limited corneal permeability of the
drugs from conventional dosage forms are responsible for low
ocular bioavailability (,5%) (Urtti, 2006; Ali and Byrne, 2008;
Huang et al., 2018). Several formulation strategies such as
ocular hydrogels, topical ocular inserts, and ointments have
demonstrated increased drug residence in the cul-de-sac
(Fathi et al., 2015; Jain et al., 2016; Adelli et al., 2017;
Balguri et al., 2017). Lately, in situ hydrogels have been
demonstrated to enhance the precorneal residence of topi-
cally instilled pharmaceutical compounds, and thereby
increase the ocular bioavailability (Mundada and Avari,
2009; Sheshala et al., 2015). These systems undergo rapid sol-to-
gel transformation in response to stimuli such as pH, electrolytes,
temperature, and photoradiation (Mundada and Avari, 2009;
Sheshala et al., 2015). Tears are rich in electrolytes, hence, the
ion sensitive in situ gel systemrapidly transforms to a hydrogel
in the ocular milieu, even at lower polymer concentrations
(Rupenthal et al., 2011; Kushwaha et al., 2012).
Drug penetration into the inner ocular tissues is restricted
by the cornea due to its distinct anatomic organization of
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epithelium, stroma, and endothelium (Ali and Byrne, 2008;
Mun et al., 2014). Nanotechnology-based formulations such
as polymeric nanoparticles or solid lipid nanoparticles, lipo-
somes, niosomes, and micelles have been reported to enhance
transcorneal drug permeability (Abdelkader et al., 2012;
Agarwal et al., 2016; Balguri et al., 2016; Duxfield et al., 2016;
Ikuta et al., 2017). Recently, a few reports in the literature have
shown the utility of advanced vesicular systems such as
bilosomes and transfersomes, which are ultra-deformable and
flexible vesicles, to enhance the permeability of drugs across
the ocular membranes (Abdelbary et al., 2016; Garg et al.,
2017). These vesicles consist of an edge activator, a hydrophilic/
amphiphilic single chain surfactant (replacing/along with
cholesterol or phospholipid), which imparts them the supe-
rior transmembrane permeability characteristics (Garg et al.,
2017).
Severalnanocarrier-loadedstimuli-responsive (pH/temperature)
in situ gel systems, such as solid lipid nanoparticles, poly-
meric nanoparticles, and nanoemulsions, which are vesic-
ular system laden in situ gels, were reported to prolong drug
residence in the precorneal space and improve permeability
across the cornea (Kumar et al., 2013; Ibrahim et al., 2016;
Pandurangan et al., 2016; Morsi et al., 2017; Paradkar
and Parmar, 2017). Recently, we demonstrated the success
of an ion-activated sol-to-gel–transforming system of bilo-
somes as a suitable ocular drug delivery platform (Janga
et al., 2018).
Gellan gum–based, electrolyte sensitive, in situ gel
systems of transfersomes have not yet been investigated.
Thus, for the first time, the current research aimed to
formulate and evaluate the electrolyte-sensitive in situ hydro-
gels of transfersomes as an effective ocular drug delivery
platform. D-alpha tocopheryl polyethylene glycol 1000 succi-
nate [tocopheryl polyethylene glycol succinate (TPGS)] was
used as an edge activator. Natamycin (NT), a macrolide
polyene antifungal agent, was selected as a model drug due to
its shortcomings in terms of precorneal residence, aqueous
solubility, and corneal permeability. NT was approved by the
US Food and Drug Administration for the treatment of ocular
fungal infections, such as fungal keratitis, and it is commer-
cially available as Natacyn (5% w/v) ophthalmic suspension
(Tanure et al., 2000). To confirm the feasibility of electrolyte-
responsive sol-to-gel–transforming NT transfersomes as a
suitable platform for ocular drug delivery, ocular safety, cytocom-
patibility, in vitro transcorneal permeability, and ocular drug
disposition, studies in New Zealand male albino rabbits
were conducted.
Materials and Methods
NTwas purchased from Cayman Chemical (Ann Arbor, MI). Phospho-
lipon (PL) 90H and Kolliphor TPGS (D-alpha tocopheryl polyethylene
glycol 1000 succinate) were obtained from Lipoid, LLC (Newark, NJ)
and BASF Corporation (Florham Park, NJ), respectively. Sorbitan
monostearate [Span 60 (S60)] and methyl thiazolyl tetrazolium
reagent (methyl thiazolyl diphenyl-tetrazolium bromide) were pur-
chased from Sigma Aldrich (St. Louis, MO). Gellan gum (GG) was
obtained from MP Biomedicals, LLC (Santa Ana, CA). Dulbecco’s
modified Eagle’s medium/nutrient mixture F-12 was ordered from
Mediatech, Inc. (Manassas, VA). Glycerin, Amicon ultracentrifugal
filters (100 kDa regenerated cellulose membrane), solvents [high-
performance liquid chromatography (HPLC) grade], and other analyt-
ical grade chemicals were purchased from Fisher Scientific (Hampton,
NH). Whole eyes of New Zealand male albino rabbits were procured
from Pel-Freez Biologicals (Rogers, AR). New Zealand male albino
rabbits were ordered from Harlan Laboratories (Indianapolis, IN).
Quantification of Natamycin. A previously reported HPLC-UV
method, with few changes, was used to determine the amount of NT
in the samples (Thangabalan andKumar, 2013). Briefly, a LunaC18(2)
100 Å phenomenex column (4.6 mm  250 mm; 5m particle size) was
connected to the Waters 600 controller pump in the HPLC system.
A mixture of 30 volumes of acetonitrile and 70 volumes of 0.02 M
potassium dihydrogen phosphate (pH 5.5) was used as the mobile
phase at a flow rate of 1.0 ml/min. With the help of a Waters 717 plus
Autosampler, a sample of 20ml was injected into the column. The drug
was detected at a lmax value of 304 nm on a Waters 2487 Dual l
Absorbance detector. The peak response was recorded using Agilent
3395 Integrator.
Preparation of Natamycin Transfersomes and In Situ Gel
Formulations. The NT transfersome formulations (FNs) were pre-
pared by the film hydration technique (Abdelkader et al., 2011; Chen
et al., 2016; Pitta et al., 2018). All formulation components were
accurately weighed and dissolved in a chloroform, ethanol, andmethanol
(7:1:2 v/v/v) solvent mix taken in a round bottom flask (Table 1). It
was then fixed to a rotary flash evaporator (Laborota 4000; Heidolph,
Germany) and operated for 30 minutes at 200 rpm to evaporate the
solvent mix, at 45 6 5°C, to form a dry residual lipid film. Deionized
water (8–10ml) with glycerin (2.25%w/v), maintained at 606 5°C, was
added to this round bottom flask and agitated to form transfersomes.
The FN-loaded formulation (FNG) was prepared by mixing fixed vol-
umes of selected FN and GG solution, maintained at 60 6 5°C (Table 2).
Both FNs and FNGs were placed in screw-capped glass vials, allowed to
attain room temperature, and stored for further characterization.
Morphometric Properties. The hydrodynamic radius or particle
size (PS) and homogeneity index [polydispersity index (PDI)] of
the transfersomes were evaluated by a Zetasizer Nano ZS Zen3600
analyzer (Malvern Instruments, UK). Double-distilled water was
filtered through 0.2 mmnylon filter and used to dilute (1000 times) the
formulations. The diluted formulations were taken in disposable clear
cells and subjected to dynamic light scattering at 25°C, utilizing a
TABLE 1
Composition and physicochemical properties of natamycin transfersomes (mean 6 S.D., n = 3)
A total of 250 mM of lipid mixture was used in all preparations. Ten milliliters of each formulation contained 10 mg of natamycin and 225 mg of glycerin.
Component/Evaluation Parameter
Formulation
FN 1 FN 2 FN 3 FN 4 FN 5 FN 6
Molar ratio (Phospholipid 90H:Span60) 2:1 1:1 1:2 2:1 1:1 1:2
Phospholipid 90H (mg) 91 122 136 82 109 123
Span60 (mg) 52 36 27 46 31 23
TPGS (mg) 10 10 10 50 50 50
PS (nm) 192.1 6 8.6 145.2 6 2.9 165.2 6 2.9 171.4 6 3.9 137.3 6 3.0 158.2 6 6.1
PDI 0.33 6 0.12 0.20 6 0.01 0.21 6 0.1 0.41 6 0.1 0.32 6 0.01 0.40 6 0.3
ZP (mV) 214.4 6 2.4 217.0 6 1.5 220.9 6 3.7 213.2 6 2.6 215.3 6 1.5 218.3 6 3.1
%EE 74.1 6 4.2 84.8 6 4.8 69.4 6 2.4 80.7 6 1.3 91.4 6 2.7 75.4 6 1.5
Drug content (%) 94.7 6 2.2 95.2 6 1.6 97.1 6 3.0 98.1 6 1.1 98.3 6 2.3 95.6 6 1.2
pH 6.3 6 0.4 6.1 6 0.7 6.9 6 0.1 6.2 6 0.5 6.1 6 0.4 6.9 6 0.1
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helium-neon laser beam of 633 nm at 173° angle of detection. Zeta
potential (ZP) readings were recorded with the laser Doppler veloc-
imetry option in the Zetasizer.
Drug Content and Entrapment Efficiency. For drug content
analysis, the formulation and solvent mixture [methanol and 190-proof
alcohol (70:30 %v/v)] were mixed in a 1:10 ratio and centrifuged
(AccuSpin 17R centrifuge; Fisher Scientific) for 20minutes at 13,000 rpm.
The supernatant was collected and drug content in the supernatant
was estimated using HPLC.
To determine the percentage of drug entrapment efficiency (%EE),
an ultra-filtration technique was adopted. A 500 ml formulation
was loaded in an Amicon ultra-centrifugal filter (Fisher Scientific),
centrifuged for 10 minutes at 5000 rpm (AccuSpin 17R centrifuge;
Fisher Scientific), and the aqueous filtrate was collected and quanti-








where Wi 5 total amount of drug in the formulation, and Wf 5 drug
amount in the aqueous phase.
Sol-To-Gel Characteristics. In situ hydrogel formation time
[gel formation time (GFT)] and intact gel residence time (GRT)
were evaluated to determine the gelling properties of the FNGs. To
determine the GFT, 50 ml FNG was added to simulated tear fluid
[(STF), 2 ml] in glass vials. The vials were placed in a reciprocating
water bath (Precision; Fisher Scientific), operated at 100 rpm and at
34°C, and the time taken to form hydrogel was recorded. These vials
were inspected visually every hour, for 12 hours, and the time point
where the hydrogel dissolved or broke was recorded as the GRT
(Nagesh et al., 2012; Paradkar and Parmar, 2017; Janga et al.,
2018).
Viscosity Determination. The rheological properties of the FNs
and FNGs and the in situ gels (formed from the corresponding FNGs)
weremeasured using aBrookfield viscometer [LVDV-II1Pro Viscometer
(cone and plate type), Middleboro, MA]. Then, 50 ml of the FN/FNG
was taken in the sample holder, the gap from CP-40 spindle to the
sample holder plate was adjusted, and the viscometer was operated
at 0.1, 1, and 10 rpm, at 25°C. The viscosity measurements were
recorded fromRheocalc software (Brookfield Engineering Laboratories,
Inc., MA). Similarly, the hydrogel viscosity was determined by adding
500 ml mixture of FNG and STF (50:7) in the sample holder plate
(Morsi et al., 2017; Janga et al., 2018).
Texture Properties Determination. The texture properties of
in situ gels from corresponding FNGs were measured on a TA.XT2i
texture analyzer (Texture Technologies Corp.) that operated in
the compression mode (Tai et al., 2014). A soft matter holder
(TA-275) that was loaded with hydrogel was situated under a
1-inch-diameter probe (TA-3), which was operated at a 0.50 mm/s
test speed with 3g trigger force until it penetrated 1 mm deep into
the hydrogel. The data were recorded at 500 points per second
acquisition rate (n 5 3).
Morphology of NT Transfersomes. Transmission electron mi-
croscopy (JEOL JEM1200EX II electronmicroscope) studies were used
to examine the morphology of the vesicles in the optimized formula-
tions (FN 2 and FNG 3) according to the earlier protocol with some
modifications (Ibrahim et al., 2013). Briefly, FN 2 and FNG 3 were
centrifuged at 25,000 rpm, at 15°C, for 1 hour (WX Ultra Series
Centrifuge; SORVALL). The transfersome pellet was separated, and
then suspended in 5 ml of deionized water and centrifuged at 2000 rpm
and 15°C for 5minutes (Eppendorf AG centrifuge,Hamburg,Germany).
The supernatant vesicular suspension was separated and diluted
(1:100) with deionized water. On a copper grid (400 mesh), 2 ml of the
diluted suspension was taken and Formvar film (Electron Microscopy
Sciences EMS, Hatfield, PA) was placed over it. The grids were kept in
a desiccator overnight to dry, and then observed under a JEOL 2000EX
transmission electron microscope fixed with a high-resolution digital
camera and monitor.
Stability Studies. The glass vials with the optimized formula-
tions were covered with aluminum foil and stored under refrigerated
conditions (2–8°C) and at 25°C for 60 days. The samples were withdrawn
at preset timepoints (0, 30, and 60days) and themorphometric properties,
%EE, and drug content were evaluated to determine the stability of the
formulations under storage conditions.
Human Corneal Limbal Epithelial Cell Cytotoxicity. A
methyl thiazolyl tetrazolium assay was employed to evaluate the
cytotoxicity of FN 2, FN 5, and FNG 3 using human corneal limbal
epithelial (HCLE) cells. Briefly, 100ml per well of HCLE cell suspension
(15  104 cell/ml) was placed in a 96-well plate (Costar 3596; Corning
Inc., Corning, NY) filled with Dulbecco’s modified Eagle’s medium/
nutrient mixture F-12 (50:50), containing 10% calf serum and 1%
penicillin/streptomycin in the culture medium. The plate was in-
cubated at 37°C in an incubator supplied with 5% CO2 for 24 hours.
Then, the medium was replaced by 100 ml of diluted formulations
(i.e., 50 ml of each sample and the culture medium), normal saline
(negative control), or triton-X-100 (positive control). The cells were
washed twice with culture medium after the incubation to ensure
complete removal of formulation. To each well, 100 ml of 1 mg/ml
methyl thiazolyl tetrazolium reagent was added in the culture
medium (without serum). The plates were incubated for 4 hours at
37°C and 5% CO2. After incubation, the formazan crystals (formed
during the incubation) were dissolved by replacing the medium with
100 ml DMSO. The color intensity was measured at 570 nm using the
m-Quant universal microplate spectrophotometer (Bio-Tek Instru-
ments, Inc., Winooski, VT). The percentage of cell viability following
TABLE 2
Composition and characterization of FN 2 in situ hydrogel formulations (mean 6 S.D.; n = 3)
A total of 250 mM of lipid mixture was used in all preparations. Ten milliliters of each formulation contained 10 mg of
natamycin and 225 mg of glycerin.
Component/Evaluation Parameter
Formulation
FN 2 FNG 1 FNG 2 FNG 3
Molar ratio (Phospholipid 90H:Span60) 1:1 1:1 1:1 1:1
Phospholipid 90H (mg) 122 122 122 122
Span 60 (mg) 36 36 36 36
TPGS (mg) 10 10 10 10
GG (mg) — 10 20 30
Viscosity (cP) (formulation) 16.8 6 3.1 18.7 6 1.5 27.5 6 1.4 39.6 6 2.6
GFT (s) — ,5 ,5 ,5
GRT (h) — ,1 3 to 4 6 to 7
Viscosity (cP) (Hydrogel) — 94.1 6 2.5 206.9 6 4.1 651.3 6 1.7
Work of adhesion (g. s) — 0.56 6 0.05 0.94 6 0.02 1.33 6 0.04
—, indicates not tested.
g. s, gram. sec.
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exposure to the test formulations was calculated relative to that of
the negative control (Janga et al., 2018).
Transcorneal Permeability. Transcorneal permeability studies
were conducted across rabbit corneas, excisedwith some scleral portion,
from rabbit whole eyes procured from Pel-Freez Biologicals. Valia-
Chien diffusion cells (PermeGear, Inc.), which were specially designed
for corneal transport/permeation studies, were used for these studies.
Unlike flat mount cells (side-by-side diffusion cells), Valia-Chien cells
are shaped like a ball and socket joint that couples the donor and
receiver cells. The cornea is mounted on the ball joint, which helps
maintain the natural shape of the cornea. The two cells are then locked
together and the central part of the cornea spreads flat across the
orifice in the center of the spherical joint. This rules out variations in
the diffusion surface area that could occur with the side-by-side cells
because of changes in the size and shape of the corneas. The corneas
were securely mounted onto the diffusion cells and maintained at
34°C, such that the endothelial side faced the receiver chamber and
the epithelial side faced the donor chamber. Then, 200 ml of the
formulations [control (Natacyn), FN 2, FN 5, and FNG3]was placed in
the donor chamber. To allow hydrogel formation from FNG 3, 50 ml of
Dulbecco’s PBS (DPBS) was added to the donor chamber of the cell,
along with the formulation. The control (Natacyn) suspension was
diluted to drug content equivalent to the tested formulations. Since
solubility of NT in DPBS (pH 7.4) with 2.5% w/v of random methyl-
beta-cyclodextrinwas higher than that in DPBS or isotonic PBS alone,
it was used as the receiving medium in the study. At predetermined
time intervals, 600 ml of the sample was collected from the receiver
cell and the same volume of fresh medium was replaced every time
to maintain a constant 5 ml of volume for 3 hours. The drug content
in the samples was analyzed using HPLC.
Transcorneal Permeability Data Analysis. The cumulative
amount of drug permeated (M), steady-state flux (J), and apparent
permeability (Papp) coefficient are the parameters that determine
trancorneal permeation of NT across the rabbit cornea (Majumdar
and Srirangam, 2009; Janga et al., 2018). Here, Mn was computed
from the following equation:




where n, Vr, Vs, and Cr(n) represent the sample time point, receiver
chamber media volume, sample volume withdrawn at any time point
(in milliliters), and drug concentration in the receiver chamber’s
media at a given time point (micrograms per milliliter), respectively.
The rate of drug permeation across the rabbit cornea wasmeasured
as the slope derived from the graph between M and time (t). The
transcorneal flux (J) of the drug was computed from the following
equation (Liu et al., 2018):
J5 ðdM=dtÞ=A (3)
where A specifies the cornea surface area (0.636 cm2).
The Papp coefficient of the drug was calculated as the ratio of
the transcorneal flux (J) and initial drug concentration in the donor
half-cell (Cd) from the following equation (Majumdar and Srirangam,
2009; Balguri et al., 2016):
Papp 5
J
Cd  60 (4)
Histology Study of the Cornea. The corneas used in the in vitro
corneal transport studies were subjected to histology evaluation to
determine any changes in corneal anatomy. Immediately after the
transcorneal permeation experiment, corneas were stored in 4% para-
formaldehyde. After embedding them in paraffin wax, these corneas
were sliced into cross sections (5 mm) with a microtome (American
Optical 820 Rotary Microtome). These slices of corneal cross sections
were taken on a glass slide and placed in the oven for overnight drying.
The paraffin traces on the slide were removed by washing with xylene
and the tissue was rinsed with water and alcohol. Then, the tissue
was washed for 10 minutes using Gill III hematoxylin nuclear dye
(StatLab Medical) for staining and eosin for counterstaining. To
remove the excess staining, the slide was again washed (with alcohol,
water, andxylene).Next, a cover slipwasplacedon the slideand the tissue
was observed through a microscope (Nikon Eclipse 800 microscope).
With the aid of PictureFrame 3.0 software (Optronics), the tissue
section images were captured.
Ocular Distribution Study. Conscious New Zealandmale albino
rabbits (2.5–3.0 kg) were used to determine the ocular distribution
of NT from the control (Natacyn) suspension, FN 2, and FNG 3. The
study was performed as per the approved protocol of the University
of Mississippi Institutional Animal Care and Use Committee and the
Association for Research in Vision and Ophthalmology statement.
The rabbits were randomly placed into three groups according to the
treatment regimen (n5 8). The right eye of each rabbit received 50 ml
(topical administration) of the corresponding formulations (Natacyn,
FN 2, or FNG 3). At predetermined time points (2 and 6 hours), four
rabbits from each group were anesthetized by ketamine and xylazine
combination intramuscular injection and sacrificed by an overdose of
pentobarbital injected through the marginal ear vein. The treatment
eye was washed with a small volume of ice cold isotonic PBS. Then,
the eyes were enucleated, and the individual ocular tissues were
carefully separated and stored (280°C).
Extraction of NT from Ocular Tissues. A protein precipitation
technique was employed to extract the NT from the different ocular
tissues, such as cornea (Cr), iris-ciliary (IC), aqueous humor (AH),
sclera (Sc), vitreous humor (VH), and retina-choroid (RC). Briefly, in
separate eppendorf tubes, Cr, IC, Sc, and RC tissues were minced and
1 ml cold methanol (0.1% w/v formic acid) was added. Then, 500 and
200 ml of cold acetonitrile (0.1% w/v formic acid) were introduced
into eppendorf tubes containing 500 ml of VH and 200 ml of AH,
respectively. All of these samples were vortexed for 30 seconds,
sonicated for 10 minutes in a bath sonicator (Fisher Scientific), and
centrifuged for 30 minutes at 13,000 rpm. In a separate vial, the
supernatant was carefully collected and stored (at280°C). The amount
of NT in the supernatant was quantified by the HPLC method de-
scribed previously (Thangabalan and Kumar, 2013). A Waters 2487
Dual l absorbance detector, set to a sensitivity of 0.05 ABSORBANCE
UNITS (FULL SCALE), (AUFS), was used to determine the NT
content in the various ocular tissues. The calibration plots were
linear [coefficient of determination (r2) $ 0.95] in all of the ocular
tissues. The extraction efficiency, limit of detection, and limit of
quantification in the various ocular tissues were 80%, 10 ng/ml,
and 20 ng/ml, respectively.
Statistical Analysis. The datawere subjected to one-wayANOVA
with Tukey’s Honestly Significant Difference (HSD) (GraphPad version
5.00; GraphPad Software, San Diego, CA) to determine the level of
statistical significance of difference, set at P , 0.05, between the
formulations.
Results and Discussion
The NT-loaded transfersome formulations were developed
successfully using S60 and PL as vesicle-forming components,
which are critical in order to obtain stable vesicles with high
drug entrapment (Rother et al., 2007; Al-Mahallawi et al.,
2015; Chen et al., 2016). Earlier reports suggested the forma-
tion of small-sized niosomes with S60 (nonionic surfactant) and
stable liposomes with PL, a saturated phospholipid that avoids
lipid oxidation-related instability of vesicles (Kulkarni et al.,
1995). In recent times, it has been demonstrated that the
incorporation of a suitable hydrophilic/amphiphilic nonionic
surfactant in the bilayer structure as an edge activator imparted
flexibility and deformability characteristics to the vesicles
(Shamma and Elsayed, 2013). Hence, TPGS (an amphiphilic
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surfactant) was used as an edge activator in the transfersomes.
All of the FNs (pH 6.1–6.9) showed drug content in the range
from 94.7%6 7.2% to 97.9%6 4.1% and demonstrated uniform
distribution of drug in the formulations (Table 1).
Morphometric Properties and %EE of the FN. The
formulation components in the vesicular systems influence
their morphometric properties such as the PS, PDI, and ZP
as well as the %EE. Hence, the impact of the PL-to-S60 molar
ratio and TPGS quantity on the properties of the transfersomes
was investigated. The PS, PDI, ZP, and %EE values of the FNs
were in the range from137.363.0 to192.168.6 nm, 0.2060.01
to 0.416 0.1,213.26 2.6 to220.96 3.7 mV, and 69.4%6 2.4%
to 91.4% 6 2.7%, respectively (Table 1).
The transfersomes in the FNs with a 1:1 molar proportion of
PL:S60 (FN 2 and FN 5) were smaller compared with the
formulations with different molar ratios (Table 1). Close
packing of the bilayer in the vesicles due to the strong
hydrophobic interactions between the S60 and fatty acid
chains of PL may result in transfersomes with a smaller
hydrodynamic radius (Shukla et al., 2016; Paradkar and
Parmar, 2017). Thus, these formulations showed higher %
EE owing to low drug leaching from the transfersomes with
tight bilayer packing (Table 1) (Shukla et al., 2016). On the
other hand, the transfersomes (FN) preparations with 2:1 and
1:2 molar proportion of PL:S60 were bigger with low %EE,
suggesting drug expulsion from the loosely packed vesicles,
which could be due to the perturbation of bilayer as the result
of an insufficient hydrophobic interaction between lipid (PL)
and surfactant (S60) (Shukla et al., 2016; Paradkar and
Parmar, 2017). Interestingly, the quantity of edge activator
(TPGS) influenced the PDI and%EE, but not the PS and ZP, in
the FNs (Table 1).
At any given PL:S60 molar ratio, the %EE and PDI of the
transfersomes increased with an increase in the amount of
TPGS, which could be attributed to the formation of drug
entrapped micelles by the excess amount of TPGS that leaked
into the dispersion medium from the bilayer of the trans-
fersomes, and thereby resulted in increased PDI (Table 1)
(Rother et al., 2007; Abdelbary et al., 2016). The FNs with
lower PDI, smaller size, and higher %EE were considered for
further investigations.
Characterization of FN In Situ Gel Systems. Gellan
gum is an anionic polysaccharide polymer with sol-to-gel trans-
formation characteristics in the presence of cations, and thus
is used as an electrolyte-sensitive gelling agent. The FNGs
were prepared by mixing FN 2 in the solution with GG (0.1%–
0.3% w/v). The concentrations of GG tested were well below
the value given in the US Food and Drug Administration
inactive ingredients database (https://www.accessdata.fda.gov/
scripts/cder/iig/index.cfm). GG has a thickening property owing
to the formation of double helices with van der Waals forces
in the aqueous environment (Morsi et al., 2017). Hence, it
was essential to evaluate the viscosity of FNGs. A linear
relationship between the concentration of GG and the viscosity
of the formulation was observed. The viscosity of the formula-
tions was below 50 cP, which would facilitate administration of
topical ophthalmic solutions (Table 2) (Uddin et al., 2017).
The GFT andGRT are critical properties that determine the
efficiency of ocular in situ gel systems (Kushwaha et al., 2012;
Kumar et al., 2013; Morsi et al., 2017). The GFT of,5 seconds
indicated the immediate sol-to-gel phase transition of the
FNG in the ocular milieu. The GRT of the hydrogel formed
from the FNG increased from,1 to 6 or 7 hours as the concen-
tration of GG increased from 0.1 to 0.3% w/v, respectively
(Table 2). An abundance of cations (mono or divalent) in the
tear fluid results in the rapid formation of an intact hydrogel
matrix by crosslinking GG to form double helix aggregates
(Rupenthal et al., 2011; Kumar et al., 2013; Morsi et al., 2017;
Pandurangan et al., 2016). Hence, the viscoelastic and work of
the adhesion properties of the hydrogels increased linearly
with the concentration of GG in the FNGs, suggesting longer
precorneal residence (Table 2) (Dintzis et al., 1970; Morsi
et al., 2017).
FNG 3with viscosity of 39.66 2.6 cP showed rapid sol-to-gel
transformation in the STF. The resulting hydrogel was intact
for .6 hours and was considered for further studies. Further-
more, transmission electron microscopy images of the trans-
fersomes confirm the smooth vesicular-layered structure in
FN 2 and FNG 3 (Fig. 1).
Cytotoxicity in HCLE Cells. In vitro cytotoxicity of
FN 2, FN 5, and FNG 3 was assessed in HCLE cells. The
percentages of cell viability of cells treated with FN 2 and
Fig. 1. Transmission electron micrographs depicting the layered morphology of transfersomes for FN 2 (A) and FNG 3 (B).
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FN 5 were 67.56 4.8 and 17.76 5.4, respectively, which were
considerably lower than that observed in the negative con-
trol group (saline). The positive control group treated with
Triton-X-100 (1%), a nonionic surfactant, showed 6.9%6 2.5%
cell viability. Hence, the drop in the percentage of cell viability
of the groups exposed to FN 2 and FN 5 might be related to
the overall nonionic surfactant composition (TPGS and S60)
in the formulations. The group treated with FN 2 (0.45% w/v
of nonionic surfactant) showed a considerably higher percent-
age of cell viability compared with FN 5 (0.86%w/v of nonionic
surfactant). Hence, it is presumed that the higher nonionic
surfactant concentration might have contributed to the lower
percentage of cell viability. However, no reports in the litera-
ture have demonstrated the corneal toxicity of the combination
of S60 and TPGS.
The higher percentage of cell viability in the FNG 3 group
suggested that the in situ hydrogels of FN 2 are well tolerated
by corneal epithelial cells (Table 3). In the cytotoxicity studies,
the HCLE cells were exposed to the formulations for 24 hours;
however,most topical ophthalmic formulationswill be in contact
with the cornea for a very short period of time owing to rapid
precorneal clearance. Thus, to further examine if the trans-
fersomes have any toxic effects on corneal anatomy, the
histology of the corneas from the in vitro transcorneal perme-
ability studies was examined.
Histology of Corneal Anatomy. The anatomic features
of the corneas tested in the corneal transport studies are
shown in Fig. 2. The intact cornea shows the stroma layer (SL)
sandwich between the epithelial layer (EPL) and endothelial
layer. Bowman’s membrane separates the EPL from the SL,
while Descemet’smembrane parts the SL from the endothelial
layer. Signs of corneal structural damage include shrinking,
breaking, or complete loss of the EPL; a gap between the EPL,
Bowman’s membrane, and the SL; and vacuoles in the SL. In
the current study, no signs of structural damage were noticed
in the corneas exposed to FN 2 and FNG 3 in the transcorneal
permeation studies (Fig. 2). Furthermore, the absence of
remarkable structural variation between these corneas and
those treated with control (NT suspension) and DPBS in-
dicated that both FN 2 and FNG 3 did not induce any toxic
effects or damage to corneal architecture (Fig. 2). On the other
hand, the corneas exposed to FN 5 (0.86% w/v of non-ionic
surfactant) showed loss of the EPL and confirmed the corneal
toxicity observed in the in vitro cytotoxicity.
Transcorneal Permeation Studies. In vitro transcor-
neal transport of NT from control, FN 2, FN 5, and FNG 3 is
illustrated in Fig. 3, where about 6.3- to 9.0-fold enhancement
in the transcorneal steady-state flux of the drug fromFN2 and
FNG 3 is observed (Fig. 3B). Furthermore, the Papp coefficient
of NT from these formulations was significantly higher than
the control suspension (P , 0.05) (Fig. 3C). These results
demonstrated the ability of the transfersomes to enhance the
NT permeability through the cornea. This is consistent with
previous literature reports that illustrate the penetration of
non-ionic surfactant-based vesicles across the cornea through
the fluidization of lipid constructs in the cornea (Dai et al.,
2013; Abdelbary et al., 2016).
Interestingly, ∼16-fold higher transcorneal flux of NT from
FN 5 was seen over the control suspension with Papp 5 3.9 
1025 Cm/s. Moreover, the transcorneal permeation parame-
ters of FN 5 were significantly superior compared with those
observed from FN 2 and FNG 3 (P , 0.05) (Fig. 3). In this
experiment, a sudden increase in the percentage of the
cumulative amount of drug permeated was noticed for
FN 5 after the 1-hour time point (Fig. 3A). This could be
attributed to corneal damage, and thus cornea anatomy
was investigated.
Ocular Drug Disposition Studies. Based on the cyto-
toxicity, histology, and transcorneal permeability studies,
FN 2 and FNG 3 were selected for ocular distribution studies
in New Zealand male albino rabbits. In the ocular drug depo-
sition studies, undiluted Natacyn suspension was used as a
control formulation to ensure no underestimation of the
marketed product performance. Since the dose of the NT
administered as FN 2 and FNG 3 was 50 times lower than
the undiluted control, the mean dose-normalized NT con-
centrations were calculated in the rabbit ocular tissues to
compare the ocular permeability of drug from these differ-
ent formulations (Fig. 4).
In the Cr and AH tissues of the rabbits administered with
FN 2 and FNG 3, the mean dose-normalized NT concentra-
tions observed at the end of 2 hours were considerably higher
compared with that found in the rabbits treated with NT
suspension, suggesting enhancement in the permeation
of drug through the Cr (P , 0.05) (Fig. 4A). The advanced
vesicles with increased amphiphilic nature, such as bilosomes
and transfersomes, owing to the presence of the edge activator
intercalates with the lipids in the corneal EPL, partitions into
the hydrophilic SL, and thereby penetrates across the endothe-
lial layer into the AH (Shamma and Elsayed, 2013; Morsi et al.,
2017; Janga et al., 2018). The poor aqueous solubility limited
permeability of NT from the control suspension could have
resulted in the low dose-normalized drug concentration in
the AH.
Themean dose-normalized concentrations of NT in the Sc of
the rabbits administered with FN 2 and FNG 3 were signif-
icantly higher compared with that noticed in the rabbit group
treated with the NT suspension (Barar et al., 2009; Al-Halafi,
TABLE 3
Percentage of cell viability of HCLE cells treated with FN 2, FN 5, and
FNG 2 in vitro cytotoxicity assay (mean 6 S.E.M.; n = 6)
Sample Number Treatment Group Cell Viability
%
1 Negative control 100.0 6 5.1
2 FN 2 67.5 6 4.8
3 FN 5 17.7 6 5.4
4 FNG 3 93.0 6 6.7
5 Positive control 6.9 6 2.5
Fig. 2. Histology images of rabbit corneas exposed to DPBS (A), control
(B), FN 2 (C), FN 5 (D), and FNG 3 (E).
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2014). This suggests the depot formation of transfersomes
in the sclera. Moreover, the drug levels alone in the RC of
the FN 2–treated rabbit group confirm the penetration
of the transfersomes across the scleral surface and thereby
into the RC (Rother et al., 2007; Chen et al., 2016) (Fig. 4). It
has been reported that the scleral tissue, in contrast to the
cornea, is 10-fold more permeable to hydrophobic than
hydrophilic compounds. Hence, the higher NT concentration
in the RC could be attributed to the higher permeability (P,
0.05) of the transfersomes due to their amphiphilic nature.
The mean dose-normalized NT levels in the IC of the FN 2–
and FNG 3–treated rabbits were significantly higher than
the control group rabbits, which demonstrates the improved
transocular membrane permeability characteristics of the
transfersomes (P , 0.05) (Dai et al., 2013; Morsi et al., 2017).
At the end of 2 hours, the drug levels noticed in the majority of
the ocular tissues in the FN 2–treated rabbits were consider-
ably higher than that administered with FNG 3, which would
be due to the sustained release of transfersomes from the
hydrogel (P , 0.05) (Bhatta et al., 2012; Abdelbary et al.,
2016).
At the 6-hour time point, in themajority of the ocular tissues
(except Sc) of the rabbit group treated with FN 2, theNT levels
were below detectable limits (Fig. 4B). However, NT was seen
in the Cr, IC, and Sc of rabbits in the control group, which
could be due to superior retention of the suspension in the
conjunctival sac and/or because of drug reservoir (depot)
formation in the Cr and/or Sc tissue. However, NT was not
detected in the RC, VH, and AH tissues. These results corrobo-
rate with a previous study that demonstrated low NT con-
centrations (,800 ng/ml) in rabbit tears 5 hours post-treatment
with the marketed suspension (Bhatta et al., 2012). In contrast
to FN 2, considerable mean dose-normalized NT concen-
trations in most of the ocular tissues (except VH) in rabbits
treated with FNG 3 confirmed increased residence of the
NT-loaded transfersome in situ gel in the precorneal space.
Higher mucoadhesion of polymer with cellular glycoproteins,
which could be attributed to the increased hydrophobic
Fig. 3. In vitro transcorneal amount permeated vs. time (A), flux (B), and Papp (C) of natamycin from control, transfersomes, and transfersomes in situ
gel formulations (mean 6 S.D.; n = 3); * significantly different from control (P , 0.05); ¥ significantly different from any formulation group (P , 0.05).
Fig. 4. Mean dose normalized natamycin levels in rabbit ocular tissues from control, transfersomes (FN 2), and transfersomes in situ gel formulations
(FNG 3), at 2-hour (A) and 6-hour (B) time points (mean6 S.E.M.; n = 4). ND, not detected; * significantly different from control (P, 0.05); ǂ significantly
different from corresponding in situ gel formulation group (P , 0.05); ¥ significantly different from any formulation group (P , 0.05).
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interactions or ionic or hydrogen bonding, leads to longer
contact time of hydrogel with the biologic membrane (Yu et al.,
1993). These results demonstrate the potential of transfersome-
loaded electrolyte-responsive sol-to-gel–transforming sys-
tems as a reliable platform for sustained ocular drug delivery.
Stability Studies. The physical stability data of FN 2
and FNG 3 stored at 4°C and 25°C for 60 days are presented
inTable4.Nosignificant changeswereobserved in themorphom-
etric properties and the %EE of both FN 2 and FNG 3 stored
under both temperature conditions. However, at the end of
60 days the PS, PDI, ZP, and %EE of FN 2 stored at 25°C
were statistically different from those observed with the
freshly prepared formulation (P , 0.05). This could be due
to the aggregation of the vesicles and drug leakage from the
vesicles. No significant variations were noticed in the prop-
erties of the FNG 3, which could be due to the low or no
aggregation of transfersomes. The higher stability of FNG
3 may be due to the presence of the GG polymer, which has a
network-like structure and could have prevented the aggre-
gation of transfersomes (Liu et al., 2008). Both formulations,
when stored under refrigerated conditions (4°C) for 60 days,
did not show significant differences in the physicochemical
properties.
Conclusions
NT transfersomes and a relevant sol-to-gel–forming system
were successfully developed. The FN composition, with a
similarmolar ratio of vesicle-formingmaterials and lower con-
centration of the edge activator (TPGS), resulted in trans-
fersomes with smaller size and higher %EE. The in situ gel,
containing 0.3%w/vGG, immediately formed a hydrogelmatrix
in the STF, with superior viscoelastic behavior and adhesive
properties. The corneal compatibility and safety of these for-
mulations were evident from the in vitro HCLE cytotoxicity
and corneal histology studies. These studies also revealed that
the transfersomes prepared with 0.45% w/v nonionic surfac-
tants were safe and compatible for ocular drug delivery. The
transcorneal permeability studies demonstrated improved
permeability of NT from the transfersome formulations in
comparison with the control suspension. Furthermore, the
amount of NT in the different ocular tissues from the FNGs
at 6 hours was significantly higher than the control suspension.
The overall results demonstrate the effectiveness of GG-based
in situ hydrogels of transfersomes as a suitable drug delivery
platform for enhanced topical ocular pharmacotherapy. Fur-
ther studies investigating the ocular disposition ofNT fromFNs
with higher drug loads is warranted.
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